Dr. Junjie Ding is a pharmacometrics researcher in Centre for Tropical Medicine and Global Health, University of Oxford. His role is to conduct clinpharm and pharmacometrics research to inform drug development and optimize dose regimen for some key infectious diseases, such as malaria, TB, Dengue fever and leishmaniasis. Currently, he is vice-chair and board member of Chinese Pharmacometrics Committee, and board member of DIA clinpharm community. His research interests are mainly on clinical PK-PD modelling and application (such as dose selection, specific population, pediatric extrapolation, ethnic sensitivity assessment, medication adherence, optimal design), translational PK-PD and PBPK modelling. He has published 30+ papers in peer reviewed journals, including top journal, like Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics. In addition, he was associate editor-in-chief of 2 textbooks of basic and advanced population PK-PD analysis.

Before his current role in academia, he was head of clinpharm department in AZ R&D China, and team leader of PKS in Novartis R&D China.  He provided professional clinpharm and pharmacometrics supports for 100 + innovative drugs development in China. Before joining industry, he worked as an associate professor in Children’s Hospital of Fudan University. 

英国牛津大学热带医学和全球健康研究中心定量药理研究人员，从事疟疾、结核、登革热和利什曼原虫等传染性疾病临床药理和定量药理研究工作。现任中国药理学会定量药理专业委员会副主任委员和常委，曾任第一届青年学组组长；DIA临床药理社区成员。主要研究方向为临床群体PK/PD建模和应用，包括剂量选择、特殊人群、儿科外推、种族敏感性评估、依从性判断、优化采样设计等；转化PK/PD建模；PBPK建模。近年来以第一作者或通讯作者在Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics等主流杂志发表论文多篇。担任《基础群体药动学和药效学分析》和《群体药动学和药效学进阶》副主编。

曾任阿斯利康全球研发（中国）有限公司临床药理负责人和诺华（中国）生物医学研究中心临床药理副总监，为100多个创新药的开发提供临床药理和定量药理的支持。加入工业界前在复旦大学附属儿科医院担任副教授从事定量药理工作。